DarioHealth Reports Third Quarter 2026 Financial Results: Year-over-Year Revenue Growth and Operating Expense Reduction

Detailed summary

DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced financial results for the third quarter ended September 30, 2026.

NEW YORK, Nov. 12, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced financial results for the third quarter ended September 30, 2026.

"In the second quarter of 2026, we described how Dario's business model is designed to support growth. We believe that our third quarter of 2026 shows that model is working, with multi-condition expansion within existing accounts and new health plan agreements through our channel partners," said Erez Raphael, Chief Executive Officer of DarioHealth. "At the same time, the market is moving toward the integrated platform we have spent more than a decade building. For years, the industry treated consumer health and payer-funded chronic care as two different businesses. We believe they are becoming one, and Dario sits exactly where they meet.

Today's consumer increasingly chooses the entry point into care, while the payer continues to fund the chronic condition behind it, and Dario believes the value in the market will move to whoever owns the path between the two. One of the largest national health insurers, an existing Dario customer, plans to implement a marketplace model that combines consumer choice with payer funding. This customer is working with Dario to extend the relationship from the digital program to delivery of the GLP-1 therapy itself. Dario views the convergence of these markets around access to specific therapies, inside a managed and measured program, as a significant opportunity.

Dario believes this shift will move chronic care management from single-condition apps to an AI-led, clinically governed system built on one member record. We believe Dario is one of very few platforms with consumer engagement and payer-grade evidence on the same member record, built over more than a decade on both sides: consumer roots and FDA-cleared connected devices in the home…

Opening of the article, excerpted from Yahoo Finance. To read the rest, open the article on the publisher's site.